Table 1.
Model Development (Population-Derived) Cohort(n=455) |
Model Validation (Referral-Derived)Cohort(n=361) |
||||||
---|---|---|---|---|---|---|---|
Patients With Available Data |
Patients With Available Data |
||||||
Characteristic | Valuea | No. | % | Valuea | No. | % | P Value |
Age, y | 43.2±5.5 | 455 | 100 | 43.0±5.4 | 361 | 100 | .43 |
Body mass index, kg/m2 | 29.4±7.5 | 411 | 90 | 29.6±7.8 | 334 | 93 | .69 |
Parity, No. | 2.0 (2.0–3.0) | 448 | 98 | 2.0 (2.0–3.0) | 359 | 99 | .12 |
Previous cesarean delivery, No. of patients (%) | 74 (16) | 417 | 92 | 78 (22) | 351 | 97 | .12 |
Tubal ligation, No. of patients (%) | 148 (33) | 455 | 100 | 176 (49) | 358 | 99 | <.001 |
Preoperative bleeding, d | 9.8±5.9 | 379 | 83 | NA | NA | NA | NA |
Preoperative accidents or blood clots, No. of patients (%) | 238 (62) | 455 | 100 | NA | NA | NA | NA |
Metrorrhagia, No. of patients (%) | 217 (48) | 455 | 100 | NA | NA | NA | NA |
Preoperative dysmenorrhea, No. of patients (%) | 22 (5) | 455 | 100 | 49 (14) | 360 | 99 | <.001 |
Uterine length, cm | 9.1±1.3 | 434 | 95 | 9.2±1.1 | 344 | 95 | .05 |
Retroverted uterus, No. of patients (%) | 27 (6) | 455 | 100 | NA | NA | NA | NA |
Hemoglobin, g/dL | 12.2±1.6 | 439 | 96 | NA | NA | NA | NA |
Preprocedure US, No. of patients (%) | 349 (77) | 455 | 100 | 195 (54) | 360 | 99 | <.001 |
Evidence of intramural fibroids, No. of patients (%) | 98 (28) | 349 | 77 | NA | NA | NA | NA |
Evidence of adenomyosis, No. of patients (%) | 20 (6) | 349 | 77 | 14 (8) | 165 | 46 | .24 |
Endometrial thickness, mm | 9.2±5.5 | 291 | 64 | 9.2±5.5 | 171 | 47 | .96 |
Duration of follow-up, y | 2.5 (1.2–3.6) | 455 | 100 | 2.7 (1.7–4.0) | 361 | 100 | .003 |
Abbreviations: IQR, interquartile range; NA, not available; US, ultrasonography.
Categorical data are presented as number of patients (percentage of sample). Continuous data are presented as mean±standard deviation for normally distributed data or median (IQR) for skewed data.